Imagen en Cardio-Oncología: técnicas de imagen en el diagnóstico y seguimiento de pacientes oncológicos
DOI:
https://doi.org/10.37615/retic.n1a3Palabras clave:
Cardiotoxicidad, Ecocardiografía, Disfunción ventricular, Fracción de ejección, Strain, Cardio-RM, Ecocardiografía tridimensional.Resumen
Los avances en el diagnóstico precoz y tratamiento del cáncer han permitido reducir la mortalidad de los pacientes, pero el tratamiento del cáncer se comporta como un nuevo factor de riesgo y se asocia a efectos secundarios graves en el sistema cardiovascular. Las técnicas de imagen constituyen una herramienta imprescindible en la monitorización de los tratamientos oncológicos. El objetivo de un seguimiento protocolizado es facilitar el proceso del cáncer identifi cando y tratando pprecozmente las complicaciones cardiovasculares en una fase reversible. Este artículo revisa las indicaciones actuales de las diferentes técnicas de imagen en la monitorización de pacientes con cáncer.
Descargas
Métricas
Citas
Tan Chiu E, Yothers G, Romond E, et al. Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, with or without Trastuzumab as Adjuvant Therapy in Node-positive Human Epidermal Growth Factor Receptor2-overexpressing Breast Cancer: NASABP B-31. J Clin Oncol 2005; 23: 7.811-7.819. DOI: https://doi.org/10.1200/JCO.2005.02.4091
Wang L, Tan T, Halpern EF, et al. Major Cardiac Events and the Value of Echocardiographic Evaluation in Patients Receiving Anthracycline-Based Chemotherapy. Am J Cardiol 2015; 116: 442-446. DOI: https://doi.org/10.1016/j.amjcard.2015.04.064
Cardinale D, Colombo a, Bacchiani G, et al. Early Detection on Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy. Circulation 2015; 131: 1.981-1.988. DOI: https://doi.org/10.1161/CIRCULATIONAHA.114.013777
Plana JC, Galderisi M, Barac A, et al. Expert Consensus for Multimodality lmaging Evaluation of Adult Patients during and after cancer Therapy: A Report from the American Society of Echocardiography and the European Association of cardiovascular Imaging. J Am Soc Echocardiogr 2014; 27: 911-939. DOI: https://doi.org/10.1016/j.echo.2014.07.012
Lang RM, Badano LP. Mor-Avi V, et al. Recommendations for cardiac chamber quantifi cation by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28: 1-39. DOI: https://doi.org/10.1016/j.echo.2014.10.003
Porter TR, Abdelmoneim S, Belcik T. Guidelines for the Cardiac Sonographer in the Performance of Contrast Echocardiography: A Focused Update from the American Society of Echocardiography. J Am Soc Echocardiogr 2014; 27: 797-810. DOI: https://doi.org/10.1016/j.echo.2014.05.011
Thavendiranathan P, Grant AD, Negishi T, et al. Reproducibility of Echocardiographic Techniques for Sequential Assessment of Left Ventricular Ejection Fraction and Volumes Application to Patients Undergoing Cancer Chemotherapy. J Am Coll Cardiol 2013; 61: 77-84. DOI: https://doi.org/10.1016/j.jacc.2012.09.035
Toro-Salazar OH, Ferranti J, Lorenzoni R, et al. Feasibility of Echocardiographic Techniques to Detect Subclinical Cancer Therapeutics-Related Cardiac Dysfunction among High-dose Patients When Compared with Cardiac Magnetic Resonance Imaging. J Am Soc Echocardiogr 2016; 29: 119-131. DOI: https://doi.org/10.1016/j.echo.2015.10.008
Oliveira GH, et al. Incidence, Predictors, and Impact on Survival of Left Ventricular Systolic Dysfunction and Recovery in Advanced Cancer Patients. Am J Cardiol 2014; 113: 1893e-1898e. DOI: https://doi.org/10.1016/j.amjcard.2014.03.018
Colombo A, et al. Cardiac complications of chemotherapy: Role of biomarkers. Curr Treat Options Cardio Med 2014; 16 (6): 313. DOI: https://doi.org/10.1007/s11936-014-0313-6
Mor-Avi V, Lang R, Badano L, et al. Current and Evolving Echocardiographic Techniques for the Quantitative Evaluation of Cardiac Mechanics: ASE/EAE Consensus Statement on Methodology and Indications Endorsed by the Japanese Society of Echocardiography. J Am Soc Echocardiogr 2011; 24: 277-313. DOI: https://doi.org/10.1016/j.echo.2011.01.015
Yingchoncharoen T, et al. Normal ranges of left ventricular strain: A metaanalysis. J Am Soc Echocardiogr 2013; 26 (2): 185-191. DOI: https://doi.org/10.1016/j.echo.2012.10.008
Cheng S, et al. Reproducibility of speckle-tracking-based strain measures of left ventricular function in a community-based study. J Am Soc Echocardiogr 2013; 26 (11): 1.258-1.266 e2. DOI: https://doi.org/10.1016/j.echo.2013.07.002
Mousavi N, et al. Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50-59% treated with anthracyclines. Eur H J Cardiovasc Imag 2015; 16: 977-984. DOI: https://doi.org/10.1093/ehjci/jev113
Thavendiranathan P, et al. Use of Myocardial Strain Imaging by Echocardiography for the Early Detection of Cardiotoxicity in Patients During and After Cancer Chemotherapy – A Systematic Review. J Am Coll Cardiol 2014; 63: 2.751-2.768.
Rhea IB, et al. Incremental prognostic value of echocardiographic strain and its association with mortality in cancer patients. J Am Soc Echocardiogr 2015; 28: 667-673. DOI: https://doi.org/10.1016/j.echo.2015.02.006
Sawaya H, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 2012; 5: 596-603. DOI: https://doi.org/10.1161/CIRCIMAGING.112.973321
Sawaya H, Plana JC, et al. Early detection and prediction of cardiotox¡city in chemotherapy-treated patients. Am J Cardiol 2011; 107: 1.375-1.380.
Negishi K, et al. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 2013; 26: 493-498. DOI: https://doi.org/10.1016/j.echo.2013.02.008
Negishi K, et al. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. Eur Heart J Cardiovasc Imaging 2014; 15 (3): 324-331. DOI: https://doi.org/10.1093/ehjci/jet159
Nolan M, Plana JC, Thavendiranathan P. Cost-eff ectiveness of strain-targeted cardioprotection for prevention of chemotherapy-induced cardiotoxicity. International Journal of Cardiology.
Haddy N, et al. Cardiac Diseases Following Childhood Cancer Treatment: Cohort Study. Circulation 2016; 133 (1): 31-38. DOI: https://doi.org/10.1161/CIRCULATIONAHA.115.016686
Saito M, et al. Association of left ventricular strain with 30-day mortality and readmission in patients with heart failure. J Am Soc Echocardiogr 2015; 28: 652-666. DOI: https://doi.org/10.1016/j.echo.2015.02.007
Rehr RB, Malloy CR, Filipchuk NG, Peshock RM. Left ventricular volumes measured by MR imaging. Radiology 1985; 156 (3): 717-719. DOI: https://doi.org/10.1148/radiology.156.3.4023232
Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, et al. Comparison of inter-study reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Am J Cardiol 2002; 90 (1): 29-34. DOI: https://doi.org/10.1016/S0002-9149(02)02381-0
Armstrong GT, Plana JC, Zhang N, Srivastava D, Green DM, Ness KK, et al. Screening adult survivors of childhood cancer for cardiomyopathy: Comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012; 30 (23): 2.876-2.884. DOI: https://doi.org/10.1200/JCO.2011.40.3584
Neilan TG, Coelho-Filho OR, Pena-Herrera D, Shah RV, Jerosch-Herold M, Francis SA, et al. Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines. Am J Cardiol 2012; 110 (11): 1.679-1.686. DOI: https://doi.org/10.1016/j.amjcard.2012.07.040
Calleja A, Poulin F, Khorolsky C, Shariat M, Bedard PL, Amir E, et al. Right Ventricular Dysfunction in Patients Experiencing Cardiotoxicity during Breast Cancer Therapy. J Oncol 2015; 2015: 609194. DOI: https://doi.org/10.1155/2015/609194
Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011; 57 (22): 2.263-2.270. DOI: https://doi.org/10.1016/j.jacc.2010.11.063
Ylänen K, Poutanen T, Savikurki-Heikkilä P, Rinta-Kiikka I, Eerola A, Vettenranta K. Cardiac magnetic resonance imaging in the evaluation of the late eff ects of anthracyclines among long-term survivors of childhood cancer. J Am Coll Cardiol 2013; 61 (14): 1.539-1.547. DOI: https://doi.org/10.1016/j.jacc.2013.01.019
Tham EB, Haykowsky MJ, Chow K, Spavor M, Kaneko S, Khoo NS, et al. Diffuse myocardial fi brosis by T1-mapping in children with subclinical anthracycline cardiotoxicity: Relationship to exercise capacity, cumulative dose and remodeling. J Cardiovasc Magn Reson 2013; 15: 48. DOI: https://doi.org/10.1186/1532-429X-15-48
Toro-Salazar OH, Gillan E, O’Loughlin MT, Burke GS, Ferranti J, Stainsby J, et al. Occult cardiotoxicity in childhood cancer survivors exposed to anthracycline therapy. Circ Cardiovasc Imaging 2013; 6 (6): 873-880. DOI: https://doi.org/10.1161/CIRCIMAGING.113.000798
Douglas PS, Hoff mann U, Patel MR, Mark DB, Al-Khalidi HR, Cavanaugh B, et al. Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med 2015; 372: 1.291-1.300. DOI: https://doi.org/10.1056/NEJMoa1415516
Newby D, Williams M, Hunter A, Pawade T, Shah A, Newby D, et al. CT coronary angiography in patients with suspected angina due to coronary heart disease (SCOT-HEART): An open-label, parallel-group, multicentre trial. Lancet 2015; 385: 2.383-2.389. DOI: https://doi.org/10.1016/S0140-6736(15)60291-4
Neglia D, Rovai D, Caselli C, Pietila M, Teresinska A, Aguadé-Bruix S, et al. Detection of signifi cant coronary artery disease by noninvasive anatomical and functional imaging. Circ Cardiovasc Imaging 2015; 8: pii: e002179. DOI: https://doi.org/10.1161/CIRCIMAGING.114.002179
Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: A collaborative British cohort study. J Natl Cancer Inst 2007; 99: 206-214. DOI: https://doi.org/10.1093/jnci/djk029
Bouillon K, Haddy N, Delaloge S, Garbay JR, Garsi JP, Brindel P, et al. Longterm cardiovascular mortality after radiotherapy for breast cancer. J Am Coll Cardiol 2011; 57: 445-442. DOI: https://doi.org/10.1016/j.jacc.2010.08.638
Lancellotti P, Nkomo VT, Badano LP, Bergler-Klein J, Bogaert J, Davin L, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: A report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr 2013; 26: 1.013-1.032. DOI: https://doi.org/10.1016/j.echo.2013.07.005
Daniëls LA, Krol DG, de Graaf MA, Scholte AJ, Van’t Veer MB, Putter H, et al. Screening for coronary artery disease after mediastinal irradiation in Hodgkin lymphoma survivors: Phase II study of indication and acceptance. Annals of Oncology 2014; 25: 1.198-1.203. DOI: https://doi.org/10.1093/annonc/mdu130
Mulrooney DA, Nunnery SA, Armstrong GT, Ness KK, Srivastava D, Donovan FD, et al. Coronary artery disease detected by coronary computed tomography angiography in adult survivors of childhood Hodgkin lymphoma. Cancer 2014; 120: 3.536-3.544. DOI: https://doi.org/10.1002/cncr.28925
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2022 Teresa L´opez Fernández, Amparo Martínez Monzonís, Esther Pérez David, Silvia Valbuena López
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
RETIC se distribuye bajo la licencia Creative Commons Reconocimiento-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0) https://creativecommons.org/licenses/by-nc-nd/4.0 que permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
- Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
- No comercial: no puede utilizar el material con fines comerciales.
- No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
- Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
